Ozanimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5 and has little activity on other S1P receptors (S1P2, S1P3, and S1P4).
The mechanism by which ZEPOSIA exerts therapeutic effects in MS is unknown but may involve the reduction of lymphocyte migration into the central nervous system.1
ZEPOSIA is part of a class of compounds classified as sphingosine-1-phosphate receptor modulators (S1PR modulators), which are used to treat patients with relapsing forms of MS, including patients with clinically isolated syndrome, relapsing remitting MS, and secondary progressive MS. ZEPOSIA keeps lymphocyte immune cells in the lymph nodes, reducing their movement into the central nervous system. In clinical trials with ZEPOSIA, the reduction in peripheral absolute lymphocyte count (ALC) was used as a pharmacodynamic marker for the mechanism of action.
This information is intended for U.S. Healthcare Professionals.